TB Pericarditis Management

Diagnostic Approach

The European Society of Cardiology recommends obtaining a chest radiograph to identify pulmonary TB, which is present in 30% of cases, and performing an echocardiogram to assess for pericardial effusion and thickening 1
Consider CT or MRI looking for pericardial thickening and mediastinal/tracheobronchial lymphadenopathy with hypodense centers, and culture sputum, gastric aspirate, and urine for M. tuberculosis in all patients 1
Calculate pericardial score in endemic areas, which includes fever, night sweats, weight loss, globulin levels, and peripheral WBC count, with a score ≥6 being highly suggestive of TB pericarditis 1
Do not rely on tuberculin skin testing as it is not helpful in adults, and consider diagnostic pericardiocentesis with tests such as direct culture for M. tuberculosis and white cell count and cytology 1

The standard 4-drug therapy consists of an intensive phase with Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol for 2 months, followed by a continuation phase with Rifampicin and Isoniazid for 4 months, with a total duration of 6 months 1, 2

The European Heart Journal recommends adjunctive prednisolone therapy, which reduces constrictive pericarditis by 46% regardless of HIV status, although it has a neutral effect on mortality, tamponade, or combined outcomes 2, 3
The total corticosteroid duration is 6 weeks, and there is an increased risk of HIV-associated malignancies with prednisolone in HIV-positive patients 2, 3

Intrapericardial urokinase may reduce constriction risk, and appropriate antibiotic therapy is essential, as even with treatment, constriction occurs in 17-40% of cases 2, 3
Constrictive pericarditis occurs in 17-40% of cases despite treatment, and very high ADA levels predict progression to constriction 3

The European Society of Cardiology recommends ADA as an important indirect test for tuberculous infection in pericardial fluid, with a sensitivity of 93% and specificity of 97% for tuberculous pericarditis when levels are ≥40 IU/L 4, 5
A "probable" diagnosis of tuberculous pericarditis can be made when there is proof of TB elsewhere in a patient with unexplained pericarditis and a lymphocytic pericardial exudate with elevated ADA levels, as suggested by the European Heart Journal 5, 6
Very high ADA levels have prognostic value for predicting progression to pericardial constriction, according to the European Heart Journal 7

Unstimulated interferon-gamma (uIFN-γ) offers superior accuracy compared to ADA for diagnosing microbiologically confirmed tuberculous pericarditis, as reported in the European Heart Journal 5
PCR testing (Xpert MTB/RIF) is more specific (100% vs. 78%) but less sensitive (75% vs. 83%) than ADA estimation for tuberculous pericarditis, according to the European Heart Journal 7

The European Heart Journal suggests that high ADA levels suggesting tuberculous pericarditis should prompt consideration of antituberculous therapy (rifampicin, isoniazid, pyrazinamide, and ethambutol) for at least 6 months 4, 5
Early diagnosis and treatment are crucial to prevent progression to constrictive pericarditis, which occurs in 17-40% of patients despite appropriate treatment, as reported in the European Heart Journal 8, 9
Adjunctive interventions such as intrapericardial urokinase and corticosteroids may be considered to reduce the risk of constrictive pericarditis, according to the European Heart Journal 10, 9

The European Heart Journal recommends performing transthoracic echocardiography to document pericardial effusion size, pericardial thickness, and assess for tamponade physiology at the start of treatment 11, 12
Obtain ECG to document baseline rhythm, voltage, and any conduction abnormalities, as recommended by the European Heart Journal 12, 13
Measure inflammatory markers including CRP and/or ESR, WBC count with differential, as suggested by the European Heart Journal 12, 14, 13
Assess renal and liver function as baseline for monitoring drug toxicity, according to the European Heart Journal 12, 14, 13
Document HIV status, as this critically impacts adjunctive corticosteroid decisions, as stated by the European Heart Journal 11, 15

Assess clinical response weekly during the first month, looking specifically for resolution of fever, night sweats, weight stabilization, and improvement in dyspnea, as recommended by the European Heart Journal 11, 15
Repeat echocardiography at 4 weeks to evaluate effusion size and assess for early signs of constriction, as suggested by the European Heart Journal 16, 12, 14, 13
If the patient is not improving or deteriorating after 4-8 weeks of ATT, pericardiectomy is recommended, according to the European Heart Journal 16, 12, 14, 13

Monitor for symptoms of constrictive pericarditis: progressive dyspnea, peripheral edema, ascites, hepatomegaly, elevated jugular venous pressure, as recommended by the European Heart Journal 16, 12, 14, 13
Track inflammatory markers (CRP/ESR) monthly to assess treatment response, as suggested by the European Heart Journal 12, 13
Monitor for drug toxicity: hepatotoxicity, peripheral neuropathy, visual changes, renal function, according to the European Heart Journal 12, 14, 13

Prednisolone may be considered in HIV-negative patients to reduce constrictive pericarditis risk by 46%, though it has neutral effect on mortality, as stated by the European Heart Journal 15
Avoid corticosteroids in HIV-positive patients due to increased risk of HIV-associated malignancies, as recommended by the European Heart Journal 11, 15
Large effusions (>20 mm diastolic echo-free space) require intensified monitoring, according to the European Heart Journal 12, 14, 13

Development of cardiac tamponade (Beck's triad: hypotension, muffled heart sounds, elevated JVP) requires immediate pericardiocentesis, as recommended by the European Heart Journal 11, 12, 15
Clinical deterioration despite 4-8 weeks of appropriate ATT requires pericardiectomy, according to the European Heart Journal 16, 12, 14, 13

European Heart Journal, 2015

European Heart Journal, 2004

European Heart Journal, 2015